Chinese biotech company Jacobio Pharma announced on Monday that it had received approval from Chinese regulatory authorities for the registration phase-3 clinical trial of a combination therapy using its SHP2 inhibitor drug candidate JAB-3312. SHP2 inhibitors are expected worldwide to have a substantial clinical effect in cancer and immunity disease treatment, and the approval made JAB-3312 the first SHP2 inhibitor to enter the phase-3 clinical study globally. The approved clinical study in China is designed to evaluate the efficacy and safety of JAB-3312 in combination with the company's other investigational drug candidate KRAS G12C inhibitor glecirasib, for treating first-line non-small cell lung cancer patients with KRAS G12C mutations. The control arm is the current standard treatment for first-line non-small cell lung cancer, which is the combination therapy of PD-1 antibody and chemotherapy. |
At least 1 dead in Florida as storms continue to pummel the South in a week of severe weatherStrong rebound to British economy ends 'technical recession'At least 1 dead in Florida as storms continue to pummel the South in a week of severe weatherJapan defense chief urges higher security after drone video of warship posted on China social mediaBiden administration will seek partial end to special court oversight of child migrantsAustralian judge extends ban on X sharing video of Sydney bishop's stabbingLast year's runnerPolice dismantle proKilling of airman by Florida deputy reminds of Black people being shot in their homesBiden administration will seek partial end to special court oversight of child migrants